Inventor · disambiguated record
Mark De Boer
Also filed as: DE BOER MARK
21 granted patents·5 pending applications·1,223 citations·filing 1992–2022
97Inventor score
Top patents by PatentIndex Score
26 records- 0198US5677165AAnti-CD40 monoclonal antibodies capable of blocking B-cell activationCHIRON CORP·Filed 1993·Granted Oct 14, 1997·212 cites·11 claims
- 0296US7790166B2Anti-CD40 antibodies capable of blocking B-cell activationNOVARTIS VACCINES & DIAGNOSTIC·Filed 2008·Granted Sep 7, 2010·32 cites·11 claims
- 0396US7361345B2Anti-CD40 antibodies capable of blocking B-cell activationNOVARTIS VACCINES & DIAGNOSTIC·Filed 2005·Granted Apr 22, 2008·27 cites·14 claims
- 0496US5874082AHumanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferationCHIRON CORP·Filed 1996·Granted Feb 23, 1999·175 cites·20 claims
- 0595US7547438B2CD40-binding activating antibodiesPANGENETICS BV·Filed 2006·Granted Jun 16, 2009·60 cites·10 claims
- 0695US6899879B2Method for treating an IgE-mediated disease in a patient using anti-CD40 monoclonal antibodiesCHIRON CORP·Filed 2001·Granted May 31, 2005·47 cites·7 claims
- 0795US6315998B1Methods of blocking B-cell activation using anti-CD40 monoclonal antibodiesCHIRON CORP·Filed 2000·Granted Nov 13, 2001·46 cites·20 claims
- 0894US6056959ACD40 antigen antibody complexCHIRON CORP·Filed 1995·Granted May 2, 2000·84 cites·8 claims
- 0994US6030915AProcess for preparing a large pore hydroprocessing catalystAKZO NOBEL NV·Filed 1997·Granted Feb 29, 2000·143 cites·7 claims
- 1092US6004552AMethods of blocking B cell proliferation using anti-CD40 monoclonal antibodiesCHIRON CORP·Filed 1995·Granted Dec 21, 1999·64 cites·20 claims
- 1192US5869050AMethods of blocking T-cell activation using anti-B7 monoclonal antibodiesCHIRON CORP·Filed 1993·Granted Feb 9, 1999·61 cites·28 claims
- 1292US5397703AMethod for generation of antibodies to cell surface moleculesCETUS ONCOLOGY CORP·Filed 1992·Granted Mar 14, 1995·57 cites·17 claims
- 1391US5747034AMethods and materials for the induction of T cell anergyCHIRON CORP·Filed 1994·Granted May 5, 1998·87 cites·17 claims
- 1490US7820807B2Gene constructs coding for CD40-binding activating antibodiesPANGENETICS BV·Filed 2009·Granted Oct 26, 2010·15 cites·6 claims
- 1590US7172759B2Induction of cytotoxic T lymphocyte responses using anti-CD40 antibodiesPANGENETICS BV·Filed 2001·Granted Feb 6, 2007·29 cites·6 claims
- 1689US11396552B2Antagonistic anti-human CD40 monoclonal antibodiesDIABETES FREE INC·Filed 2020·Granted Jul 26, 2022·3 cites·20 claims
- 1775US6893553B1Hydroprocessing catalyst and use thereofNIPPON KETJEN CO LTD·Filed 2000·Granted May 17, 2005·14 cites·12 claims
- 1867US6127299AProcess for preparing a hydroprocessing catalyst from waste hydroprocessing catalystFiled 1996·Granted Oct 3, 2000·40 cites·6 claims
- 1960US2023059094A1Improved antagonistic anti-human cd40 monoclonal antibodiesDIABETES FREE INC·Filed 2022·Application pending·0 cites
- 2053US2007009517A1Method of inducing immune toleranceDE BOER MARK·Filed 2004·Application pending·0 cites
- 2148US6334947B1Catalyst comprising at least a hydrogenation metal component and a synthetic clay and a process of usingAKZO NOBEL NV·Filed 1995·Granted Jan 1, 2002·13 cites·10 claims
- 2247US6346248B1Methods of treating autoimmune diseases with a CD86-specific immunotoxinINNOGENETICS NV·Filed 1999·Granted Feb 12, 2002·9 cites·4 claims
- 2344US2016151486A1CD40 Signalling Inhibitor and a Further Compound, Wherein the Further Compound is a Bile Acid, a Bile Acid Derivative, an TGR5-Receptor Agonist, an FXR Agonist or a Combination Thereof, for the Treatment of Chronic Inflammation, and the Prevention of Gastrointestinal Cancer or FibrosisFAST FORWARD PHARMACEUTICALS B V·Filed 2014·Application pending·0 cites
- 2441US2021332131A1COMPOSITIONS AND METHODS COMPRISING IgA ANTIBODY CONSTRUCTSTIGATX INC·Filed 2021·Application pending·0 cites
- 2539US6071519AImmunotoxins specific for CD86 expressing cellsINNOGENETICS NV·Filed 1996·Granted Jun 6, 2000·5 cites·5 claims
- 2628US2017354681A1T cell-based immunotherapeuticsBCRT HOLDING BV·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →